Oncology articles from across Nature Portfolio

Epstein–Barr virus is associated with cancer and implicated in autoimmune diseases. Three studies reveal desmocollin 2 and R9AP as receptors for Epstein–Barr virus infection, highlighting new avenues for targeted therapies.

Final results from the phase I AMPLIFY-201 trial show that ELI-002 2P, a therapeutic cancer vaccine targeting mutant KRAS, elicits polyfunctional T cell responses in patients with minimal residual disease-positive pancreatic or colorectal cancer. Importantly, the magnitude of this response correlated with improved clinical outcomes. Herein, we discuss how these results could set the stage for ongoing randomized trials.

CPT2 downregulation promotes colorectal cancer proliferation by enhancing GPAT4-mediated glycerophospholipid biosynthesis and activating selective autophagy.

While CDK4/6 inhibitors improved clinical outcomes in HR⁺HER2^- metastatic breast cancer (MBC), resistance invariably occurs. The underlying molecular mechanisms are not actionable, leaving limited therapeutic options for progressing patients. Recent data highlight a role for IL-6 in the resistance of HR⁺HER2^- MBC to CDK4/6 inhibition, potentially opening novel avenues forward.

Epstein–Barr virus is associated with cancer and implicated in autoimmune diseases. Three studies reveal desmocollin 2 and R9AP as receptors for Epstein–Barr virus infection, highlighting new avenues for targeted therapies.

Final results from the phase I AMPLIFY-201 trial show that ELI-002 2P, a therapeutic cancer vaccine targeting mutant KRAS, elicits polyfunctional T cell responses in patients with minimal residual disease-positive pancreatic or colorectal cancer. Importantly, the magnitude of this response correlated with improved clinical outcomes. Herein, we discuss how these results could set the stage for ongoing randomized trials.